Drug Shortage Report for CEFTAZIDIME FOR INJECTION, USP

Last updated on 2020-08-05 History
Report ID 118930
Drug Identification Number 00886971
Brand name CEFTAZIDIME FOR INJECTION, USP
Common or Proper name Ceftazidime for Injection, USP
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) CEFTAZIDIME
Strength(s) 1G
Dosage form(s) POWDER FOR SOLUTION
Route of administration INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS
Packaging size 20ML
ATC code J01DD
ATC description OTHER BETA-LACTAM ANTIBACTERIALS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2020-06-25
Actual start date 2020-06-25
Estimated end date Unknown
Actual end date 2020-07-31
Shortage status Resolved
Updated date 2020-08-05
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v7 2020-08-05 French Compare
v6 2020-08-05 English Compare
v5 2020-06-26 English Compare
v4 2020-06-25 French Compare
v3 2020-06-25 English Compare
v2 2020-06-25 French Compare
v1 2020-06-25 English Compare

Showing 1 to 7 of 7